Mahamaya Lifesciences IPO Analysis, Allotment, And GMP

Mahamaya Lifesciences IPO- Company Analysis 

Mahamaya Lifesciences IPO under the SME IPO category is a book build issue of Rs. 70.44 Cr by Mahamaya Lifesciences Ltd., which was incorporated in 2002 and has been manufacturing and supplying life science and pharmaceutical products. It has a diversified portfolio of specialty chemicals and intermediates used in pharma and biotech research. It has its headquarters in New Delhi and has a customer-centric model assisted by superior R&D and in-house quality systems. 

The company is expanding its capacity and degree of automation in processes to realise higher output at lower operational costs.

Mahamaya Lifesciences IPO Details

The Mahamaya Lifesciences IPO date of opening is 11 November 2025, its initial public offering will end on 13 Nov, IPO allotment on Nov 14 and refund initiation on Nov 17, 2025.

The Rs. 70.44 crore new SME IPO comprises a combination of fresh issue of 0.56 crore shares (Rs. 64.28 Cr) and offer for sale of 0.05 crore shares (Rs. 6.16 Cr).

The Mahamaya Lifesciences IPO listing date (expected) might be on Tuesday, Nov 18, 2025, and listing at the BSE and SME. 

The Mahamaya Lifesciences IPO price band is Rs. 108 to Rs. 114.

IPO Timetable (Tentative)

Events	Date
IPO Opening Date	Nov 11, 2025
IPO Closing Date	Nov 13, 2025
IPO Allotment Date	Nov 14, 2025
Refund Initiation	Nov 17, 2025
IPO Listing Date	Nov 18, 2025

 

Click to open demat account and apply for the IPO.

 

Company Financials

(Amount in Cr)

Period Ended	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	188.35	112.07	77.88
Total Income	267.17	162.83	137.40
Profit After Tax	12.94	5.22	3.75
EBITDA	24.64	13.36	8.91
Net Worth	49.42	24.66	19.44
Reserves and Surplus	31.66	23.41	18.19
Total Borrowing	58.11	54.63	24.37

 

Cash Flows

(Amount in lac)

Net Cash Flow	31 Mar 2025	31 Mar 2024	31 Mar 2023
Net Cash Flow Operating Activities	52.43	(2,266.00)	106.66
Net Cash Flow Investing Activities	(828.34)	(200.15)	(279.35)
Net Cash Flow Financing Activities	852.48	2,434.92	235.49

Revenue Bifurcation

(Source: RHP)

The Objective of the Issue

The company desires to use the Net Proceeds from the Issue to fulfill its following goals:

• Purchase of Equipment for the existing Formulation plant. ~ Rs. 3.75 Cr.

• Funding capital expenditure towards setting up a new technical manufacturing plant. ~ Rs. 29.42 Cr.

• Construction of Warehouse Building and Purchase of Machinery. ~ Rs. 2.53 Cr.

• Funding the working capital requirements of our Company. ~ Rs. 18 Cr.

• General corporate purposes. 

Listed Peers of Mahamaya Lifesciences Ltd.

Company Name	Face Value (Rs. )	EPS (Rs. )	P/E Ratio (x)
Nova Agritech Limited	2	3.05	56.37
Bhagiradha Chemicals & Industries Ltd.	1	1.14	247.63

 

Valuation

KPI	Values
ROE	34.94%
ROCE	23.15%
Debt/Equity	1.08
RoNW	26.19%
PAT Margin	4.84%
EBITDA Margin	9.22%
Price to Book Value	9.40

 

 

 

Evaluation of P/E Ratio

Considering the period ended on FY 2025 with an EPS of Rs. 7.60 from the last year, the resulting P/E ratio is 15x.

Explore the Lenskart Solutions IPO.

IPO's Strengths

• Constructive R&D with well-seasoned promoters.

• Increasing RoNW and NAV with keen financial discipline.

• Operational efficiency with scalable manufacturing.

• Established relations with pharmaceutical and chemical sector majors.

IPO’s Weaknesses

• Limited product lines leading to high revenue concentration risk.

• Fluctuating raw material costs.

• Highly competitive and regulated pharmaceutical chemicals sector.
  
  

Mahamaya Lifesciences IPO GMP (Grey Market Premium)

Mahamaya Lifesciences IPO GMP today is Rs. 0, as of 08 Nov 2025 at the time of writing this information.

Mahamaya Lifesciences IPO Summary

The Mahamaya Lifesciences IPO has a market maker portion size of 309600 Shares (Rs. 3.53 Cr).

IPO Opening & Closing Date	11 Nov, 2025 to 13 Nov, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 108 to Rs. 114 per Share.
Lot Size	1200 Shares
Issue Size	61,78,800 Shares (Rs. 70.44 Cr)
Offer for Sale	5,40,000 Shares (Rs. 6.16 Cr)
Fresh Issue	53,29,200 Shares (Rs. 60.75 Cr)
Listing at	BSE, SME
Issue Type	Book build issue IPO
Registrar	Kfin Technologies Ltd.

IPO Lot Details 

Retail investors can invest in a minimum and maximum of 2 Lots (2400 Shares) for Rs. 2,73,600 and in multiples thereof, while for S-HNI investors, the minimum Lot is 3 (3600 Shares) for Rs. 4,10,400.

Minimum Lot Investment (Retail)	2 Lots
Maximum Lot Investment (Retail)	2 Lots
S-HNI (Min)	3 Lots

 

Mahamaya Lifesciences IPO Allotment Status

To check the Mahamaya Lifesciences IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.

Using BSE Website - ​BSE IPO allotment status

Promoters And Management of Mahamaya Lifesciences Ltd.

• Mr. Krishnamurthy Ganesan

• Mrs. Lalitha Krishnamurthy

• Mr. Prashant Krishnamurthy.

Pre-Issue Promoter Shareholding	77.27%
Post-Issue Promoter Shareholding	56.35%

IPO Lead Managers

• Oneview Corporate Advisors Pvt. Ltd. 

Dividend Policy

The company has not declared a dividend during the last three financial years.

 

 

Conclusion

The company behind Mahamaya Lifesciences IPO is continuously growing its profitability and return on net worth, both of which indicate improved capital usage. The company's long-term commitment to high-quality production is encouraging, and it is also growing its manufacturing facilities. However investors need to consider how competitive the market is and how unpredictable the industry is.

 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.